PI 3-Kinase Signaling Pathways joint with Inositide Signaling in Pharmacology and Disease Organizer(s): Bart Vanhaesebroeck, Sabina Cosulich and Ramon Parsons Date: February 13 - 18, 2011
Location: Keystone Resort, Keystone, CO, USAThe PI 3-kinase signaling pathway controls multiple physiological processes including cell growth, cell proliferation and cell movement. Dysregulation of this pathway in cancer, inflammation and heart disease has led to the emergence of PI 3-kinase as a promising therapeutic target. One of the most exciting developments in this field is the development of new PI 3-kinase inhibitors that are currently entering the clinic. The balance between modulating PI 3-kinase activity in a pathophysiological setting, while avoiding unwanted side effects, is the subject of intense debate. In addition, as PI 3-kinase is a member of a multigene family, the rationale for inhibiting individual isoforms or multiple isoforms of PI 3-kinase is constantly changing. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and (pre)clinical data with new PI 3-kinase inhibitors. Scholarship Deadline: October 14 2010 Discounted Abstract Deadline: October 14 2010 Abstract Deadline: November 18 2010 Discounted Registration Deadline: December 14 2010 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
AstraZeneca
Calistoga Pharmaceuticals, Inc.
Genentech, Inc.
Sanofi US
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:  |